期刊名称：MEDICAL MYCOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Medical Mycology
|
Medical Mycology is an international journal which focuses on original and innovative studies of all aspects of medical, veterinary and environmental mycology. The topics include, but are not limited to mycological, biochemical and molecular investigations of etiological agents of mycoses; aspects of pathogenesis, immunology, and epidemiology of mycotic diseases; case reports of unusual medical or veterinary fungal infections; laboratory approaches to the identification of fungal pathogens, antifungal therapy and prophylaxis; mode of action, pharmacokinetics and assessments of new antifungal agents; investigations of the mycological aspects of the indoor environment, with a focus on human and animal health. The aim of the journal is to present the best scientific reports from throughout the world and in so doing to provide a comprehensive reference base for medical mycologists, microbiologists, clinicians, and environmental specialists |
 |
.
Abstracting & Indexing
Medical Mycology is covered by BIOBASE/Current Awareness in Biological Sciences, Current Contents, FO:VM, Global Health, Index Medicus/MEDLINE, ISI; Scopus and Science Citation Index.
Instructions to Authors
The official publication of the International Society for Human and Animal Mycology (ISHAM), Medical Mycology, is an international journal, which focuses on original and innovative studies of all aspects of medical, veterinary and environmental mycology. The topics include, but are not limited to mycological, biochemical and molecular investigations of etiological agents of mycoses; aspects of pathogenesis, immunology, and epidemiology of mycotic diseases; case reports of unusual medical or veterinary fungal infections; laboratory approaches to the identification of fungal pathogens, antifungal therapy and prophylaxis; mode of action, pharmacokinetics and assessments of new antifungal agents; investigations of the mycological aspects of the indoor environment, with a focus on human and animal health. The aim of the journal is to present the best scientific reports from around the world and in so doing to provide a comprehensive reference base for medical mycologists, microbiologists, clinicians, and environmental specialists.
Types of Papers Considered for Publication
1. Types of Papers
1.1.Original Papers. Manuscripts must have: (a) a Cover-Page which includes the full title and a short title, name(s) and affiliation(s) of all author(s), full postal address, telephone and fax numbers, and email address for the corresponding author and a list of up to five keywords; (b) a separate page for a Summary of no more than 200 words prepared without sub headers; (c) text consisting of Introduction, Materials & Methods, Results, Discussion and References; (d) References must be numbered sequentially in the order in which they first appear in the text, the numbers cited in the text within non-superscript, square brackets, e.g., [1] and included in the same numerical order in the Reference section; (e) each Table should be submitted as a separate file (page) and should have footnoted descriptions of all abbreviations contained in the Table (see section below on Tables for more detailed information); (f) each Figure should be submitted as a separate file (page), with appropriate figure legends allowing a reader to understand their contents without reference to the text (see section below on Figures for more detailed information). Manuscripts MUST be in English, double-spaced, in no less than size 12 font, without line numbering and no more than 10 print pages (approximately 25 manuscript pages), including cover-page, abstract, text, references, and tables/figures.
1.2 Reviews. Authors must first electronically submit an outline of their proposed article for evaluation by the journal. The outline should be no more than two, double-spaced pages in 12 font, in which the authors describe the objectives and contents of the report. The outline must be submitted to the Reviews Editor, Wiley Schell: wiley.schell@duke.edu. Once the proposal has been evaluated, the authors will be informed of the results of the Review Editor’s initial consideration of their proposal. Reviews are NOT restricted by the formatting or length requirements of Original Papers. NOTE - the journal does NOT accept uncommisioned reviews for publication.
1.3 Case Reports. Such articles must make a distinct, novel contribution to the understanding of the etiologic agents, its clinical manifestations, and/or its treatment. They should NOT be based merely on the first incidence of a known cosmopolitan or widely distributed etiologic agent in the nation of the authors’ residence. This type of paper MUST include mycological information, e.g., the methods used to recover the etiologic agent in culture, the procedures used in its identification, etc., as well as the clinical features of the patient. Reports describing new etiologic agents should be substantiated by living cultures of the isolates deposited in an internationally recognized professional culture collection (i.e. one that has full-time staff dedicated to receiving, preserving and shipping of cultures). In addition, it is recommended that discussions of unusual or rare fungal pathogens be supported by the deposition of the organisms in recognized fungal collections. Alternatively, species identification may be supported by the sequencing of recognized genes using appropriate primers and subsequent comparison of the obtained sequences with those in GenBank or other recognized molecular databases. Nucleotide and/or amino acid sequence data should be deposited in Genbank or Swiss-Prot and the accession numbers included in the Material and Methods section or in figures of phylogenetic trees. Manuscripts MUST be in English and prepared as is an original article, EXCEPT that each should consist of a Cover page, Abstract, Introduction, Case Report, Discussion and References. These papers should be no more than 10 print pages (approximately 25 manuscript pages).
1.4 Short Communications. These manuscripts are to provide an opportunity for the presentation of preliminary or brief observations that do not warrant an original paper. The manuscript should be prepared as is an original paper, except they may be no more than 5 print pages (approximately 12 manuscript pages) including cover-page, abstract, text, references, and tables/figures.
1.5 Letters to the Editor. Letters are to allow readers the opportunity to discuss issues related to previous published original articles, case reports or short communications and should not be used for the presentation of the authors’ preliminary data from their own investigations. Letters should be no more than 5 double-spaced manuscript pages (approximately 2 print pages) in not less than size 12 font, including references.
2. Submission of Manuscripts
All submissions MUST be uploaded as Word files to the Medical Mycology ScholarOne Manuscript site at mc.manuscriptcentral.com/tmmy. Users who have not previously submitted work through this site must create an account from the link on the login page. Assistance with this and all other areas of the site is available in the User Guide, which is accessed via the ‘Get Help Now’ button at the top right corner of all ScholarOne Manuscript web pages.
Manuscript Structure
1. Preparation of Manuscripts
As indicated, manuscripts MUST be in English, double-spaced, in no less than size 12 font, organized as appropriate for the manuscript type and have one (1) inch margins all around. Statistics and measurements should be given in numerals when followed by a unit, e.g., mg, ml, etc. In contrast, numerals employed in other circumstance, e.g. two patients, should be spelled out. All abbreviations, even those commonly used in medical mycology, e.g., Sabouraud glucose agar (SGA) must be defined when first used in the abstract and text.
2. References
In preparing your citations please note that software programs available to format references DO NOT presently contain an option for Medical Mycology or for the use of the Vancouver system. Consequently, such programs should be used cautiously and should be carefully reviewed by the authors to ensure that citations meet the style/format requirements of the journal. References must be numbered sequentially in the order in which they first appear in the text, the numbers cited in the text within square brackets, i.e., [1] and included in the same numerical order in the Reference section. Citation numbers MUST not be indicated in superscript. Articles with six (6) or more authors are to be cited by the names of the first three (3) authors, with the remaining authors included by et al. Journal names must be abbreviated, in italic font, without the use of periods. The volume number must be in bold font, issue numbers should not be included and all page numbers must appear for each citation (e.g. 105-107, NOT 105-7).
2.1. Journal article
Author AB, Author CD, Author EF, et al. [if six or more] Title of paper. J Title Abbrev 1995; 00: 000-000. If the title is in a language other than English, the authors should provide the English translation and the name of the original language within a bracket following the citation.
2.2. Book chapter
Author AB, Author CD, Author EF, et al. [if six or more] Chapter title. In: Editor AB, Editor CD, eds. Book Title With Initial Uppercase Letters (as indicated here and in italic font), 5th edn. Place: Publisher, 1995: 000-000.
2.3. Book
Author AB, Author CD (eds). Book Title With Initial Uppercase Letters (as indicated here and in italic font), 5th edn. Place: Publisher, 1995.
2.4. Thesis
Author AB. Paper title with lowercase initials to all words. PhD thesis, University, 1995.
2.5. Conference proceedings/Supplements
Author AB. Paper title. In: Editor AB, ed. Proceedings Title, place, date. Place: publisher, 1995: 000-000.
2.6. Meeting abstracts
Abstracts of works presented at scientific meetings should be cited in brackets within the text of the manuscripts rather than in the Reference sections. The citations should be formatted as: Author AB. Abstract title. Name of meeting, its location, the date and abstract number.
2.7. Personal communications, Unpublished results etc
References to personal communications, unpublished results and papers submitted for publication (but not yet accepted) should only appear in brackets in the text, and in the following form: [A. B. Author, unpublished results] or [C. D. Author, personal communication].
2.8. Journal article on the Internet
Abood S. Quality improvement initiative in nursing homes: the ANA acts in an advisory role. Am J Nurs [serial on the Internet]. 2002 Jun [cited 2002 Aug 12];102(6):[about3 p.]. Available from:
2.9. Monograph on the Internet
Foley KM, Gelband H, editors. Improving palliative care for cancer [monograph on the Internet]. Washington: National Academy Press; 2001 [cited 2002 Jul 9]. Available from:
2.10. Homepage/Web site
Cancer-Pain.org [homepage on the Internet]. New York: Association of Cancer Online Resources, Inc.; c2000-01 [updated 2002 May 16; cited 2002 Jul 9]. Available from: http://www.cancer-pain.org
2.11. Part of a homepage/Web site
American Medical Association [homepage on the Internet]. Chicago: The Association; c1995-2002 [updated 2001 Aug 23; cited 2002 Aug 12]. AMA Office of Group Practice Liaison; [about 2 screens]. Available from:
2.12. Database on the Internet
Open database:
Who’s Certified [database on the Internet]. Evanston (IL): The American Board of Medical Specialists. c2000-[cited 2001 Mar 8]. Available from:
Closed database:
Jablonski S. Online Multiple Congential Anomaly/Mental Retardation (MCA/MR) Syndromes [database on the Internet]. Bethesda (MD): National Library of Medicine (US). c1999 [updated 2001 Nov 20; cited 2002 Aug 12]. Available from:
2.13. Part of a database on the Internet
MeSH Browser [database on the Internet]. Bethesda (MD): National Library of Medicine (US); 2002-[cited 2003 Jun 10]. Meta-analysis; unique ID: D015201; [about 3 p.]. Available from: Files updated weekly.
3. Tables
Tables should present only essential data, must be numbered sequentially in the order in which they first appear in the text, and all should be referred to in the text. Each table should be supplied as a separate file and never imbedded within the body of the text. The table header should be brief and self explanatory and if it contains generic and species names, the latter must be spelled out in full, e.g., Candida albicans, not C. albicans. Column headings should be brief and include units in parentheses where applicable. Only horizontal rule lines should be used and then only for headers and footers.
4. Figures/Images
Images should be submitted as TIF, EPS, PDF or JPG (preferred) files. Scanned images should be of a sufficient resolution, i.e., 300 dpi for halftones/color, 500 dpi for combination halftones and 1000–1200 dpi for line art. Illustrations should be submitted separate from the manuscript text file, either as individual files or together in a single file. The journal has a limited number of free colour pages within its annual page allowance provided by the publisher. Authors should consult the editorial office at submission stage as they may be required to pay a fee to guarantee colour reproduction in the print version of the journal. However, any figure submitted as a colour original may appear in colour within the journal's on-line edition, without any charges being assessed to the authors. NO part of any image may be enhanced, removed, relocated, or introduced after the capture of the original image unless the authors provide the editor with a clear and accurate description of the nature of the image manipulation.
5. Nomenclature
Proposals of new fungal taxa MUST conform to the requirements of the current edition of the International Code of Botanical Nomenclature and be supported, as indicated in the discussion of Case Report, by deposition of cultures and/or the unique nucleotide and/or amino acid sequences in appropriate collections or databases, along with the new binomial. In addition, current binomials should appear in italics, must be spelled out in full when first used in the abstract, text, figures/tables. Thereafter, a generic name may be abbreviated to the first initial only, e.g. Candida albicans when first cited and C. albicans in the remainder of the abstract and text. Species names may NEVER be used without the generic full name or abbreviation combined with the full name of the specie. For example, it must be Candida albicans or C. albicans, but never albicans, or C. neoformans var. grubii but never var. grubii. The use of abbreviations of generic and species names, e.g., (Ca) for C. albicans, in the text is NOT permitted.
6. Nucleotide and/or Amino Acid Sequence Data
Nucleotide and/or amino acid sequence data should be deposited and the GenBank/EMBL/DDBJ accession numbers should be included in the Materials and Method Section of the manuscript. However, in a phylogenetic tree of the figure, the numbers should be shown along with species names (e.g., Malassezia globosa AB099880) (No descriptions are needed in the Materials and Method Section in this case).
Required Statements
1. Humans in Research
When reporting investigations involving human subjects, authors should indicate in the manuscript if the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation within their institutions and/or with the Helsinki Declaration of 1975, as revised in 1983.
2. Animals in Research
Manuscripts containing information related to the experimental use of animals must clearly state that the studies complied with relevant professional and institutional animal welfare policies. Specifically, that procedures involving animals conformed to the ILAR Guide for the Care and Use of Laboratory Animals (1996 and later editions) of the Institute of Laboratory Animal Research, Commission on Life Sciences, National Research Council (www.nap.edu/catalog/5140.html).
3. Safety Precautions
Manuscripts describing the manipulation of cultures of fungal pathogens or toxins included in the US Department of Health and Human Services and/or the US Department of Agriculture list of human or animal Select Agents (available at www.selectagents.gov), or organisms that have been classified as Risk Group III agents by their home country or by an international regulatory agency, MUST contain a discussion of the biosafety procedures and laboratory containment facilities used and any additional precautions employed to ensure the safety of support personnel.
4. Authorship Contributions
Please note that you and your co-authors in submitting this manuscript are confirming that all authors have (a) made a substantial contribution to conception and design, acquisition of data, and/or analysis and interpretation of data, (b) participated in the drafting of the article or revising it critically for important intellectual content, (c) have read and approved the final manuscript, AND (d) that the manuscript is not, either in whole or in part, currently under consideration by any other scientific journal and has not been previously published in either hard copy or electronic format. Submissions with ten (10) or more authors will only be considered if the corresponding authors provide, in their cover letters, descriptions of each of the authors’ contributions. Manuscripts drafted or written, in whole or part, by individuals other than those indicated as authors will NOT be considered for publication unless the contributions of these individuals are clearly and accurately presented in the Acknowledgement section of the paper.
5. Acknowledgements
The work of other individuals who assisted in the studies or in the preparation of the submission must be specifically indicated in the Acknowledgment section of the paper.
6. Disclosures of Potential Conflicts of Interest
While there is no standard definition of Conflict of Interest, the United States National Institutes of Health has published the following statement:
"It is the sole responsibility of authors to disclose any affiliation with any organization with a financial interest, direct or indirect, in the subject matter or materials discussed in the manuscript (such as consultancies, employment, expert testimony, honoraria, speakers bureaus, retainers, stock options or ownership) that may be perceived as potentially affecting the conduct or reporting of the work submitted. All sources of funding are to be explicitly stated. If uncertain as to what might be considered a potential conflict of interest, authors should err on the side of full disclosure" (i.e., when in doubt, provide full disclosure).
In addition, a conflict of interest may be perceived to exist in such situations as when authors are affiliated with or employed by a private enterprise whose product or competitor’s product, e.g., drug, device, diagnostic kit, is the focal point of the paper.
Information about potential conflict of interest should be clearly stated at the point of submission. This may be made available to reviewers and may be published with the manuscript at the discretion of the Editors and Publisher. The journal recommends that you and your co-authors include the sub header, “Conflict of Interest”, in the Acknowledgment section at the end of your manuscript. If no such conflict exists, simply respond “None”. If you or your co-authors have received funding that meets the criteria described in the paragraph above, the source(s) of the funds must be declared (NOTE – you are NOT required to disclose the amounts of funding that you or your co-authors have received). Furthermore, authors must indicate their employment if describing their or other companies’ products.
The intent of this policy is not to prevent authors with these relationships from publishing work, but rather to adopt transparency such that readers can make objective judgments on conclusions drawn.
Post Acceptance Information
1. Electronic Proofs
When proofs are ready, corresponding authors will receive e-mail notification with a password and Web address from which to download a PDF. Hard copies of proofs will NOT be mailed. To avoid delays in publication, corrections to proofs must be returned, by fax or as an e-mail attachment, within 48 hours of receipt.
2. Offprints
Corresponding authors will receive either fifty printed offprints or a PDF of the final published version of the paper. Preferences should be stipulated when returning proofs.
3. Copyright
It is a condition of publication that authors assign copyright or licence the publication rights of their articles, including abstracts, to ISHAM. This enables us to ensure full copyright protection and to disseminate the article, and the journal, to the widest possible readership in print and electronic formats as appropriate. Authors may, of course, use the article elsewhere after publication without prior permission from Informa UK Ltd., provided that acknowledgement is given to the journal as the original source of publication, and that Informa Healthcare is notified so that records show that its use was properly authorized. Authors retain a number of other rights under the Informa UK Ltd. rights policies documents.
4. NIH Public Access Policy
In consideration of the National Institutes of Health (NIH) and Wellcome Trust Public Access Policies, Informa Healthcare acknowledges that the broad and open dissemination of NIH/Wellcome-funded research benefits future scientific endeavour. Because we value the contribution our journals make to the body of scientific knowledge, our policies accommodate authors who wish to submit to PubMed Central/UK PubMed Central.
- Informa Healthcare will deposit funded work to PubMed Central/UK PubMed Central for public access posting 12 months (NIH) or 6 months (Wellcome Trust) after final publication in electronic form.
- 'Funded work' shall be defined as the final peer-reviewed manuscript, which was accepted for publication and that reflects any author-agreed changes made in response to the peer review.
- This embargo period begins upon final publication of the article in print or electronic form (whichever is the sooner).
Editorial Board
Chief Editor
Ira F. Salkin - Adjunct Associate Professor, State University of New York
Editorial Office address - 14 Winding Ridge Road, West Sand Lake, NY 12196, USA
Reviews Editor
Wiley Schell - Duke University Medical Center, USA
Associate Editors
R. Ashbee -Leeds General Infirmary, UK
T. Boekhout - CBS, The Netherlands
M. Brandt -Centers for Disease Control and Prevention, USA
K. Clemmons - Stanford University, USA
C. Cooper - Youngstown State University, USA
D. Elad -Kimron Veterinary Institute, Israel
J. Guarro -Universitat Rovira I Virgili, Spain
D. Kontoyiannis - The University of Texas, USA
W. Meyer -University of Sydney/Westmead Hospital, Australia
T. G. Mitchell - Duke University Medical Center, USA
D. H. Pincus - BioMerieux, Inc., USA
L-A. Pirofski - Albert Einstein College of Medicine, USA
R. Puccia -Disciplina de Biologica Celular, Brazil
G. San-Blas - Center of Microbiology and Cell Biology, Venezuela
W. Schell - Duke Medical Center, USA
D. Soll -The University of Iowa, USA
T. Sugita - Meiji Pharmaceutical University, Japan
D. A. Sutton - The University of Texas Health Science Center, USA
Editorial Board
D. Andes - USA
S. Arunmozhi Balajee - USA
S. Chatellier - France
E.C. Cole - USA
A. Fothergill - USA
T.M. Gupta - India
L. Hall - USA
A. Hasegawa - Japan
Z.U. Khan - Kuwait
C. Lass-Flörl - Austria
M. McCullough - Australia
W.G. Merz - USA
H. Mora-Montes - Scotland
R. Negroni - Argentina
E. Segal - Israel
J.F. Staab - USA
L.J. Thompson - USA
R.L. Walker - USA
A. Warris - The Netherlands
A. K. Zaas - USA
|
刊名字顺( Alphabetical List of Journals):
返回页首 